The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study.
Deirdre Jill Cohen
Honoraria - Genentech
Paul J. Christos
No relevant relationships to disclose
Hedy Lee Kindler
Honoraria - Genentech
Research Funding - Genentech
Daniel Virgil Thomas Catenacci
Honoraria - Genentech
Tanios B. Bekaii-Saab
Consultant or Advisory Role - Genentech; Sanofi
Sanaa Tahiri
No relevant relationships to disclose
Yelena Yuriy Janjigian
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Michael K. Gibson
No relevant relationships to disclose
Emily Chan
Consultant or Advisory Role - Genentech
Lakshmi Rajdev
No relevant relationships to disclose
Susan Urba
No relevant relationships to disclose
James Lloyd Wade
No relevant relationships to disclose
Peter Kozuch
No relevant relationships to disclose
Erica Love
No relevant relationships to disclose
Katherine Vandris
No relevant relationships to disclose
Naoko Takebe
No relevant relationships to disclose
Howard S. Hochster
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Joseph A. Sparano
Consultant or Advisory Role - Genentech